MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial

Bibliographic Details
Main Authors: Romano, Emanuela, Michielin, Olivier, Voelter, Verena, Laurent, Julien, Bichat, Hélène, Stravodimou, Athina, Romero, Pedro, Speiser, Daniel E, Triebel, Frédéric, Leyvraz, Serge, Harari, Alexandre
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021605/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021605/

Similar Items